

	All	Western Europe	Southern Europe incl Israel/Argentina	Northern Europe	East Central Europe	Eastern Europe
<b>Number under follow-up at 01/01/2016</b> n (% of total)	12,327 (100)	2,955 (24)	3,258 (26)	2,473 (20)	1,853 (15)	1,788 (15)
<b>Number of clinics included</b>	100	24	21	22	16	17
<b>Sex</b> n (% of all)						
Male	8,993 (73.0)	2,281 (77.2)	2,362 (72.5)	1,968 (79.6)	1,365 (73.7)	1,017 (56.9)
Female	3,334 (27.0)	674 (22.8)	896 (27.5)	505 (20.4)	488 (26.3)	771 (43.1)
<b>Current age in years, median (IQR)</b>	50 (42-56)	53 (47-59)	51 (45-56)	53 (47-59)	44 (38-51)	38 (34-43)
<b>HIV transmission category</b> n (% of all)						
MSM	4,493 (36.4)	1,309 (44.3)	1,032 (31.7)	1,352 (54.7)	719 (38.8)	81 (4.5)
IDU	3,351 (27.2)	515 (17.4)	1,065 (32.7)	364 (14.7)	526 (28.4)	881 (49.3)
Heterosexual	3,615 (29.3)	795 (26.9)	961 (29.5)	622 (25.2)	462 (24.9)	775 (43.3)
Other/unknown	868 (7.0)	336 (11.4)	200 (6.1)	135 (5.5)	146 (7.9)	51 (2.9)
<b>Ethnic origin white</b> n (% of all)	10,650 (86.4)	2,251 (76.2)	2,961 (90.9)	1,823 (73.7)	1,838 (99.2)	1,777 (99.4)
<b>Years since HIV-diagnosis, median (IQR)</b>	16.6 (10.1-23.1)	19.9 (13.0-24.5)	19.6 (12.0-24.8)	20.1 (13.7-25.2)	12.8 (7.9-18.1)	9.6 (5.4-13.6)
<b>Years on ART, median (IQR)</b>	13.3 (7.0-19.1)	17.0 (9.5-20.2)	16.3 (8.2-20.0)	16.9 (9.8-19.9)	10.4 (5.9-15.3)	5.5 (3.2-8.3)
<b>Date of enrolment into EuroSIDA</b> MM/YY, median (IQR)	06/08 (11/01-04/14)	07/08 (03/99-03/12)	03/08 (05/99-09/14)	12/05 (03/97-05/12)	07/08 (10/02-05/12)	04/12 (04/08-10/14)
<b>CD4 cell nadir</b> median (IQR) cells/mm <sup>3</sup>	218 (105-354)	188 (63-320)	248 (129-402)	200 (96-331)	242 (129-370)	210 (115-324)
<b>CD4 at enrolment</b> median (IQR) cells/mm <sup>3</sup>	410 (258-604)	421 (252-628)	435 (273-655)	380 (240-570)	412 (277-580)	395 (251-562)
<b>On ART at 01/01/2016</b> n (% of all)*						
Yes	11,741 (95.2)	2,896 (98.0)	3,177 (97.5)	2,406 (97.3)	1,766 (95.3)	1,496 (83.7)
No	586 (4.8)	59 (2.0)	81 (2.5)	67 (2.7)	87 (4.7)	292 (16.3)

<b>HIV-RNA at enrolment</b> n (% of all)**						
< 500copies/mL	7,181 (69.0)	1,961 (75.7)	1,919 (71.3)	1,384 (69.2)	1,171 (69.7)	746 (51.4)
≥ 500copies/mL	3,233 (31.0)	628 (24.3)	774 (28.7)	617 (30.8)	508 (30.3)	706 (48.6)
<b>HIV-RNA at 01/01/2016</b> n (% of all)**						
< 500copies/mL	11,383 (93.9)	2,864 (98.1)	3,075 (96.1)	2,404 (98.0)	1,722 (93.4)	1,318 (77.1)
≥ 500copies/mL	742 (6.1)	56 (1.9)	125 (3.9)	48 (2.0)	121 (6.6)	392 (22.9)
<b>Previous AIDS-diagnosis at 01/01/2016</b>						
n (% of all)	3,308 (26.8)	899 (30.4)	865 (26.6)	658 (26.6)	452 (24.4)	434 (24.3)
Yes	9,019 (73.2)	2,056 (69.6)	2,393 (73.5)	1,815 (73.4)	1,401 (75.6)	1,354 (75.7)
No						
<b>HCV status</b>						
Anti-HCV negative	6,403 (51.9)	1,641 (55.5)	1,613 (49.5)	1,611 (65.1)	1,022 (55.2)	516 (28.9)
Anti-HCV positive	5,706 (46.3)	1,269 (42.9)	1,597 (49.0)	815 (33.0)	812 (43.8)	1,213 (67.8)
Unknown	218 (1.8)	45 (1.5)	48 (1.5)	47 (1.9)	19 (1.0)	59 (3.3)
<b>People with ≥1 plasma sample</b> n (% of all)	7,767 (63.0)	2,056 (69.6)	1,627 (49.9)	2,009 (81.2)	1,635 (88.2)	449 (25.1)

**Table 1: Characteristics of EuroSIDA participants under ongoing follow-up as per 1<sup>st</sup> January 2016.** Enrolment is enrolment into the EuroSIDA study. Regions are as defined in figure 2. \* ART defined as taking any ART-regimen, regardless of the number of antiretroviral drugs. \*\* HIV-RNA among those with an available measurement.